Search Result

Results for "

gastric acid secretion and

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (2) Akt (2) Amino Acid Decarboxylase (2) Amylin Receptor (3) Anaplastic lymphoma kinase (ALK) (1) AP-1 (1) Apoptosis (25) Atg8/LC3 (11) ATP Synthase (1) Autophagy (19) Bacterial (27) Bcl-2 Family (10) Biochemical Assay Reagents (2) Bombesin Receptor (1) Calcium Channel (2) Caspase (1) CCR (2) CGRP Receptor (1) Cholecystokinin Receptor (20) COX (4) CRFR (2) CTLA-4 (1) CXCR (1) Cytochrome P450 (12) Drug Derivative (3) Drug Intermediate (1) Drug Metabolite (5) EGFR (1) Endogenous Metabolite (3) ERK (4) Exosomes (2) GABA Receptor (1) GCGR (1) GHSR (1) GLP Receptor (10) Glutathione Peroxidase (2) Glycosidase (1) HBV (1) Histamine Receptor (46) Insulin Receptor (15) Interleukin Related (16) Isotope-Labeled Compounds (21) Lipase (1) mAChR (9) MDM-2/p53 (2) MHC (1) Mitochondrial Metabolism (1) MMP (1) Mucin (1) Myosin (1) Na+/K+ ATPase (20) Neurokinin Receptor (3) Neurotensin Receptor (2) NF-κB (7) NO Synthase (1) Notch (1) p38 MAPK (10) Parasite (1) PD-1/PD-L1 (1) Phosphodiesterase (PDE) (1) PKA (1) Potassium Channel (3) Prostaglandin Receptor (3) Proton Pump (41) Reactive Oxygen Species (ROS) (1) Reference Standards (25) SARS-CoV (1) Secretin Receptor (2) SOD (2) TGF-beta/Smad (1) TNF Receptor (13) Toll-like Receptor (TLR) (1) TRP Channel (1) α-synuclein (8)
By Research Areas:	Cancer (64) Cardiovascular Disease (7) Endocrinology (46) Infection (19) Inflammation/Immunology (58) Metabolic Disease (80) Neurological Disease (32)

By Targets:

Adrenergic Receptor (2)

Akt (2)

Amino Acid Decarboxylase (2)

Amylin Receptor (3)

Anaplastic lymphoma kinase (ALK) (1)

AP-1 (1)

Apoptosis (25)

Atg8/LC3 (11)

ATP Synthase (1)

Autophagy (19)

Bacterial (27)

Bcl-2 Family (10)

Biochemical Assay Reagents (2)

Bombesin Receptor (1)

Calcium Channel (2)

Caspase (1)

CCR (2)

CGRP Receptor (1)

Cholecystokinin Receptor (20)

COX (4)

CRFR (2)

CTLA-4 (1)

CXCR (1)

Cytochrome P450 (12)

Drug Derivative (3)

Drug Intermediate (1)

Drug Metabolite (5)

EGFR (1)

Endogenous Metabolite (3)

ERK (4)

Exosomes (2)

GABA Receptor (1)

GCGR (1)

GHSR (1)

GLP Receptor (10)

Glutathione Peroxidase (2)

Glycosidase (1)

HBV (1)

Histamine Receptor (46)

Insulin Receptor (15)

Interleukin Related (16)

Isotope-Labeled Compounds (21)

Lipase (1)

mAChR (9)

MDM-2/p53 (2)

MHC (1)

Mitochondrial Metabolism (1)

MMP (1)

Mucin (1)

Myosin (1)

Na+/K+ ATPase (20)

Neurokinin Receptor (3)

Neurotensin Receptor (2)

NF-κB (7)

NO Synthase (1)

Notch (1)

p38 MAPK (10)

Parasite (1)

PD-1/PD-L1 (1)

Phosphodiesterase (PDE) (1)

PKA (1)

Potassium Channel (3)

Prostaglandin Receptor (3)

Proton Pump (41)

Reactive Oxygen Species (ROS) (1)

Reference Standards (25)

SARS-CoV (1)

Secretin Receptor (2)

SOD (2)

TGF-beta/Smad (1)

TNF Receptor (13)

Toll-like Receptor (TLR) (1)

TRP Channel (1)

α-synuclein (8)

By Research Areas:

Cancer (64)

Cardiovascular Disease (7)

Endocrinology (46)

Infection (19)

Inflammation/Immunology (58)

Metabolic Disease (80)

Neurological Disease (32)

193

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Art. -Nr.	Produktname	Target	Forschungsgebiete	Chemical Structure

HY-P1097

Gastrin I, human 15+ Cited Publications	Cholecystokinin Receptor	Endocrinology
Gastrin I, human is the endogenous peptide produced in the stomach, and increases gastric acid secretion via cholecystokinin 2 (CCK2) receptor.

HY-P0276

GIP, human 2 Publications Verification gastric Inhibitory Peptide (GIP), human	Insulin Receptor	Metabolic Disease
GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .

HY-B0377

Famotidine 5+ Cited Publications MK-208	Histamine Receptor	Cardiovascular Disease Metabolic Disease Endocrinology Cancer
Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

HY-17021

Esomeprazole 3 Publications Verification (S)-Omeprazole; (-)-Omeprazole	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-17623

Tegoprazan 2 Publications Verification CJ-12420; RQ-00000004	Proton Pump Potassium Channel Na+/K+ ATPase	Inflammation/Immunology
Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a reversible, orally active and highly selective inhibitor of gastric H ⁺/K ⁺-ATPase. Tegoprazan inhibits gastric acid secretion and motility against porcine, canine and human H ⁺/K ⁺-ATPase with IC₅₀ values ranging from 0.29-0.52 μM in vitro. Tegoprazan significantly improves colitis and enhances the intestinal epithelial barrier function in mice. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .

HY-P0276A

GIP, human TFA 2 Publications Verification gastric Inhibitory Peptide (GIP), human TFA	Insulin Receptor	Metabolic Disease
GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human TFA acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .

HY-P1070

Amylin, amide, human DAP amide, human	Amylin Receptor	Metabolic Disease
Amylin, amide, human, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .

HY-103261

SCH28080	Proton Pump	Endocrinology
SCH28080 is a reversible, K ⁺-competitive inhibitor of the gastric H,K-ATPase, with a K_i of 0.12 μM. SCH28080 is an effective inhibitor of acid secretion in vivo and with anti-gastric ulcer activity .

HY-N7067

Revaprazan hydrochloride 2 Publications Verification	Proton Pump Bacterial COX NF-κB ERK Akt	Infection Inflammation/Immunology
Revaprazan hydrochloride is reversible proton pump inhibitor. Revaprazan hydrochloride can inhibit gastric acid secretion and protect gastric mucosa. Revaprazan hydrochloride can inhibit IkappaB-alpha degradation as well as Akt inactivation, resulting in attenuation of H. pylori-induced COX-2 expression. Revaprazan hydrochloride can be used for the researches of infection and inflammmation, such as H. pylori-infected gastric inflammation and gastric ulcer .

HY-N3031

Grosvenorine	Bacterial Apoptosis Bcl-2 Family MDM-2/p53 Glutathione Peroxidase SOD TNF Receptor Interleukin Related	Infection Inflammation/Immunology
Grosvenorine is an orally active flavonoid glycoside found in S. grosvenorii. Grosvenorine exhibits antibacterial, antioxidant and antiinflammation activities. Grosvenorine can induce apoptosis and increases anti-apoptotic Bcl-2 protein expression and reduces pro-apoptotic P53 protein expression in gastric tissues. Grosvenorine enhances mucin/glycoprotein secretion, regulates gastric pH, and reduces gastric lesion incidence.Grosvenorine increases glutathione peroxidase, catalase, and SOD levels, reduces lipid peroxidation (MDA), and lowers TNF-α and IL-6 levels. Grosvenorine can be used for the researches of bacterial infection and Gastric ulcer .

HY-P3579

Gastric Inhibitory Peptide, porcine GIP (1-42), porcine	Insulin Receptor	Metabolic Disease
Gastric Inhibitory Peptide (GIP (1-42)), porcine is a porcine glucose-dependent insulinotropic polypeptide and inhibitor of pentagastrin-stimulated gastric acid secretion. Gastric Inhibitory Peptide, porcine stimulates endogenous somatostatin release. Gastric Inhibitory Peptide, porcine acts in a dose- and time-dependent manner in conscious, chronic gastric fistula-equipped rats .

HY-125556

Tetragastrin 1 Publications Verification Cholecystokinin tetrapeptide; CCK-4	Cholecystokinin Receptor	Metabolic Disease
Tetragastrin (Cholecystokinin tetrapeptide; CCK-4) is the C-terminal tetrapeptide of gastrin. Tetragastrin can stimulate gastric secretion . Tetragastrin is a Cholecystokinin (CCK-4) receptor agonist . Gastric mucosal protection .

HY-B1478

Dimaprit dihydrochloride	Histamine Receptor NO Synthase	Endocrinology
Dimaprit dihydrochloride is a selective histamine H2 receptor agonist, it also inhibits nNOS with an IC₅₀ of 49 μM. Dimaprit dihydrochloride can stimulate gastric acid secretion .

HY-P0253

Xenopsin	Neurotensin Receptor	Metabolic Disease
Xenopsin, a neurotensin-like octapeptide from Xenopus laevis skin . Xenopsin is an inhibitor of Tetragastrin stimulated gastric acid secretion .

HY-B1475

Anisotropine bromide Octatropine bromide	mAChR	Neurological Disease Metabolic Disease
Anisotropine (Octatropine) bromide is an orally active anticholinergic muscarinic antagonist. Anisotropine bromide can inhibit gastric acid secretion and is used as an adjunct to peptic ulcers .

HY-B0305A

Roxatidine Acetate Hydrochloride HOE 760	Histamine Receptor	Metabolic Disease Inflammation/Immunology Cancer
Roxatidine Acetate Hydrochloride is a potent, selective, competitive and orally active histamine _H2-receptor antagonist. Roxatidine Acetate Hydrochloride has antisecretory potency against gastric acid secretion. Roxatidine Acetate Hydrochloride can also suppress inflammatory responses and can be used for gastric and duodenal ulcers research. Roxatidine Acetate Hydrochloride has antitumor activity .

HY-17021B

Esomeprazole potassium salt 2 Publications Verification (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research .

HY-P1139

Cortistatin-8 PCFWKTCK	GHSR	Metabolic Disease
Cortistatin-8 (CST-8; PCFWKTCK), a neuropeptide, is a GHS-R1a antagonist by counteracting the response of ghrelin on gastric acid secretion. Cortistatin-8 can modulate GH release from somatotroph cells. Cortistatin-8 is a synthetic CST-analogue devoid of any binding affinity to SST-R but capable to bind the GHS-R1a. Cortistatin-8 can exert antagonistic effects on ghrelin actions either in vitro or in vivo in animals .

HY-U00360

(Rac)-Sograzepide (Rac)-Netazepide; (Rac)-YF 476; (Rac)-YM-220	Cholecystokinin Receptor	Metabolic Disease
(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor, and has the potential of reducing the secretion of gastric acid.

HY-P2416

Gastrin I, rat Rat Gastrin-17	Cholecystokinin Receptor	Endocrinology
Gastrin I, rat (Rat Gastrin-17) is a peptide hormone, can stimulate gastric acid secretion potently .

HY-P1784A

Secretin, canine TFA	Secretin Receptor	Endocrinology
ecretin, canine TFA is an endocrine hormone that stimulates the secretion of bicarbonate-rich pancreatic fluids. Secretin, canine TFA can regulates gastric chief cell function and paracellular permeability in canine gastric monolayers by a Src kinase-dependent pathway .

HY-B1789A

Telenzepine dihydrochloride	mAChR	Neurological Disease
Telenzepine dihydrochloride is a selective and orally active muscarinic M1 receptor antagonist with a K_i of 0.94 nM. Telenzepine dihydrochloride inhibits gastric acid secretion and has antiulcer effects .

HY-103281

Litorin	Bombesin Receptor	Metabolic Disease
Litorin, an amphibian bombesin peptide derivative, is an bombesin receptor agonist. Litorin stimulates the contraction of smooth muscle, stimulates gastrin, gastric acid, and pancreatic secretion, and suppresses the nutriment in vivo .

HY-W008614

Lansoprazole sulfone 1 Publications Verification AG-1813	Drug Metabolite Proton Pump	Metabolic Disease
Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H ⁺, K ⁺-ATPase. Lansoprazole sulfone can significantly stimulates gastric acid secretion by inhibiting H ⁺, K ⁺-ATPase. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .

HY-P1806A

Gastrin I (1-14), human TFA	Cholecystokinin Receptor	Metabolic Disease Endocrinology
Gastrin I (1-14), human TFA is 1-14 fragment of human gastrin I peptide. Gastrin I is an endogenous, gastrointestinal peptide hormone. Gastrin is the major hormonal regulator of gastric acid secretion .

HY-121851

Revaprazan SB 641257	Proton Pump Bacterial COX NF-κB ERK Akt	Infection Inflammation/Immunology
Revaprazan (SB 641257) is reversible proton pump inhibitor. Revaprazan can inhibit gastric acid secretion and protect gastric mucosa. Revaprazan can inhibit IkappaB-alpha degradation as well as Akt inactivation, resulting in attenuation of H. pylori-induced COX-2 expression. Revaprazan can be used for the researches of infection and inflammmation, such as H. pylori-infected gastric inflammation and gastric ulcer .

HY-B1557

Betazole 1 Publications Verification Ametazole	Histamine Receptor	Metabolic Disease
Betazole (Ametazole), a pyrazole analogue of histamine, is an orally active histamine H2 receptor agonist. Betazole induces gastric acid secretion and causes an immediate and significant increase in common bile duct pressure. Betazole is used as a diagnostic agent known as histalog for investigating gastric acid secretory capacity .

HY-129923

(R)-Omeprazole sodium	Cytochrome P450	Neurological Disease
(R)-Omeprazole sodium is a gastric acid resistant compound with activity to inhibit gastric acid secretion. (R)-Omeprazole sodium is metabolized in vivo, and its metabolism is primarily affected by cytochrome P450 enzymes. The interaction between (R)-Omeprazole sodium and mannitol may affect its bioavailability in formulations. (R)-Omeprazole sodium exhibits reversible direct and metabolism-dependent inhibition of CYP2C19 .

HY-W002039

3-Amino-3-phenylpropionic acid DL-β-Phenylalanine	Biochemical Assay Reagents	Endocrinology
3-Amino-3-phenylpropionic acid (DL-β-Phenylalanine) is a structural GABA analogue. 3-Amino-3-phenylpropionic acid inhibits baclofen (HY-B0007) induced gastric acid secretion .

HY-129415

Esaprazole Hexaprazole	Drug Derivative	Others
Esaprazole (Hexaprazole) is an antiulcer agent that has the effect of promoting the healing of peptic ulcer. Esaprazole can inhibit the secretion of gastric acid and pepsin .

HY-19105A

IT 066 hydrochloride	Histamine Receptor	Inflammation/Immunology
IT 066 hydrochloride is a Histamine H₂ receptor antagonist. IT 066 hydrochloride possesses antioxidant activity and can protect rats against acute gastric mucosal injury induced by ischemia-reperfusion. IT 066 hydrochloride can also inhibit secretagogue-induced gastric acid secretion in rats and exert a long-acting anti-lesion effect on experimental gastric and duodenal lesions in rats. IT 066 hydrochloride is applicable for the research of gastrointestinal diseases .

HY-101646

Saviprazole HOE-731	Proton Pump	Inflammation/Immunology
Saviprazole (HOE-731) is a H ⁺,K ⁺-ATPase inhibitor. Saviprazole inhibits gastric acid secretion. Saviprazole inhibits histamine- and dbcAMP-stimulated [ ¹⁴C]aminopyrine uptake, dbcAMP-induced oxygen consumption. Saviprazole can be used in research related to gastrointestinal diseases, such as gastric ulcers and acid reflux .

HY-B1557A

Betazole dihydrochloride Ametazole dihydrochloride	Histamine Receptor	Metabolic Disease
Betazole (Ametazole) dihydrochloride, a pyrazole analogue of histamine, is an orally active H2 receptor agonist. Betazole dihydrochloride induces gastric acid secretion, and causes an immediate and significant increase in common bile duct pressure. Betazole dihydrochloride has been used as a diagnostic agent known as histalog, for investigating gastric acid secretory capacity .

HY-17623R

Tegoprazan (Standard) CJ-12420 (Standard); RQ-00000004 (Standard)	Reference Standards Proton Pump	Metabolic Disease
Tegoprazan (Standard) is the analytical standard of Tegoprazan. This product is intended for research and analytical applications. Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H ⁺/K ⁺-ATPase that could control gastric acid secretion and motility, with IC₅₀ values ranging from 0.29-0.52 μM for porcine, canine, and human H ⁺/K ⁺-ATPases in vitro .

HY-17623S

Tegoprazan-d6 CJ-12420-d₆; RQ-00000004-d₆	Proton Pump Na+/K+ ATPase	Metabolic Disease
Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC₅₀ values ranging from 0.29-0.52 μM for porcine, canine, and human H ⁺/K ⁺-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .

HY-106550

Enprostil RS 84135	Prostaglandin Receptor	Endocrinology
Enprostil (RS 84135) is a prostaglandin E2 derivative. Enprostil can inhibit amogastrin-stimulated gastric acid secretion, as well as reducing the secretion of pepsin. Enprostil can also serve as an antiulcer agent, used for research of duodenal or gastric ulcers .

HY-124742

AR-HO47108	Na+/K+ ATPase	Others
AR-HO47108 is an orally active reversible Na+/K+ ATPase inhibitor. AR-HO47108 reversibly blocks the final step of gastric acid secretion by competitively binding to the potassium ion binding site of the Na+/K+ ATPase in the gastric wall cells. AR-HO47108 can be used for research on diseases related to excessive gastric acid secretion, such as peptic ulcers .

HY-167698

Dibenamine	Histamine Receptor Adrenergic Receptor	Inflammation/Immunology
Dibenamine is an alpha-adrenergic antagonist that exhibits the ability to block both basal and histamine-stimulated gastric acid secretion, making it therapeutically relevant in conditions involving excessive gastric acid production.

HY-75424A

2-(Trifluoromethyl)cinnamic acid	Proton Pump	Inflammation/Immunology
2-(Trifluoromethyl)cinnamic acid is a cinnamic acid derivative that inhibits the proton pump (H ⁺/K ⁺-ATPase), thereby reducing gastric acid secretion. 2-(Trifluoromethyl)cinnamic acid also improves delayed gastric emptying and can be used in research on gastric diseases such as acute gastritis and gastric ulcers .

HY-U00360R

(Rac)-Sograzepide (Standard) (Rac)-Netazepide (Standard); (Rac)-YF 476 (Standard); (Rac)-YM-220 (Standard)	Reference Standards Cholecystokinin Receptor	Metabolic Disease
(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor, and has the potential of reducing the secretion of gastric acid.

HY-116777

Impromidine SKF 92676	Histamine Receptor	Others
Impromidine (SKF 92676) is a potent agonist for histamine H2 receptor. Impromidine induces gastric mucosal blood flow and acid secretion .

HY-117216

L-703606	Neurokinin Receptor	Neurological Disease
L-703606 is a potent, selective antagonist of NK1 receptor. L-703606 can be used for study of gastric acid secretion .

HY-17507E

S-Pantoprazole sodium trihydrate	Proton Pump Bacterial	Infection
S-Pantoprazole (sodium trihydrate) is related to Pantoprazole (HY-17507) that plays an important roles in gastric acid secretion disorder-related diseases, or as proton pump inhibitor .

HY-165498

AU-461	Na+/K+ ATPase	Metabolic Disease
AU-461 is an orally active and reversible inhibitor of the gastric H⁺/K⁺ ATPase with IC₅₀ values for rabbit-derived and pig-derived enzymes are 12.15 μM and 4.20 μM respectively. AU-461 competes with activated cationic K⁺ (Kᵢ = 1.64 μM). AU-461 reduces both histamine-stimulated gastric acid secretion and basal gastric acid secretion in rats. AU-461 inhibits ulcer formation caused by ethanol or sodium hydroxide, and restores the plasma gastrin level to normal. AU-461 can be used for the study of peptic ulcers .

HY-P1806

Gastrin I (1-14), human	Cholecystokinin Receptor	Metabolic Disease Endocrinology
Gastrin I (1-14), human is 1-14 fragment of human gastrin I peptide. Gastrin I is an endogenous, gastrointestinal peptide hormone. Gastrin is the major hormonal regulator of gastric acid secretion .

HY-W009934

2-Phenyl-2-(2-pyridyl)acetonitrile α-Phenyl-2-pyridineacetonitrile	Drug Metabolite	Endocrinology
2-Phenyl-2-(2-pyridyl)acetonitrile is the major metabolite of SC 15396 metabolized by the supernatant fraction of rat liver homogenate. SC 15396 is an antigastrin that inhibits gastric secretion .

HY-17623D

Tegoprazan Benzoate CJ-12420 Benzoate; RQ-00000004 Benzoate	Proton Pump	Metabolic Disease
Tegoprazan Benzoate is the benzoate form of Tegoprazan (HY-17623). Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H ⁺/K ⁺-ATPase that could control gastric acid secretion and motility, with IC₅₀ values ranging from 0.29-0.52 μM for porcine, canine, and human H ⁺/K ⁺-ATPases in vitro .

HY-126751

DBM-819	Na+/K+ ATPase	Metabolic Disease
DBM-819 is a reversible inhibitor of H⁺/K⁺-ATPase (H ⁺/K ⁺-ATPase), with an IC₅₀ value of 5 μM. DBM-819 can reversibly block gastric acid secretion by inhibiting the proton pump in the gastric mucosa. It shows significant protective effects against duodenal ulcers induced by Cysteamine (HY-77591), gastric ulcers induced by Indomethacin (HY-14397), and gastric ulcers induced by Aspirin (HY-14654), with EC₅₀ values of 6, 3.1, and 4 mg/kg respectively. DBM-819 can be used in ulcer prevention research .

HY-W011245

Ranitidine S-oxide	Drug Metabolite	Metabolic Disease
Ranitidine S-oxide is the metabolite of Ranitidine (HY-B0693). Ranitidine is a potent, selective and orally active histamine H2-receptor antagonist with an IC₅₀ of 3.3 μM that inhibits gastric secretion .

HY-19010A

BMY-25368 hydrochloride SKF 94482 hydrochloride	Histamine Receptor	Neurological Disease
BMY-25368 hydrochloride is a histamine H2 receptor antagonist that acts as a gastric acid secretion inhibitor. BMY-25368 hydrochloride competitively antagonizes gastric secretion stimulated by histamine and also antagonizes gastric secretion stimulated by Pentagastrin (HY-A0261), Bethanechol (HY-B0406), and food .

Art. -Nr.	Produktname	Type

HY-W002039

3-Amino-3-phenylpropionic acid DL-β-Phenylalanine	Biochemical Assay Reagents
3-Amino-3-phenylpropionic acid (DL-β-Phenylalanine) is a structural GABA analogue. 3-Amino-3-phenylpropionic acid inhibits baclofen (HY-B0007) induced gastric acid secretion .

HY-B0377G

Famotidine (GMP) MK-208 (GMP)	Biochemical Assay Reagents
Famotidine GMP (MK-208 GMP) is Famotidine (HY-B0377) produced in GMP guideline. Famotidine GMP is a competitive histamine H2-receptor antagonist, inhibits gastric secretion, activates the gastric mucosal defensive mechanisms. Famotidine GMP ameliorates peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD) in rats model .

Art. -Nr.	Produktname	Target	Research Area

HY-114118

Semaglutide Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P1097

Gastrin I, human 15+ Cited Publications	Cholecystokinin Receptor	Endocrinology
Gastrin I, human is the endogenous peptide produced in the stomach, and increases gastric acid secretion via cholecystokinin 2 (CCK2) receptor.

HY-P0276

GIP, human 2 Publications Verification gastric Inhibitory Peptide (GIP), human	Insulin Receptor	Metabolic Disease
GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .

HY-114118B

Semaglutide acetate Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118A

Semaglutide TFA Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P0276A

GIP, human TFA 2 Publications Verification gastric Inhibitory Peptide (GIP), human TFA	Insulin Receptor	Metabolic Disease
GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human TFA acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .

HY-114118CP

Semaglutide (crude)	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide (crude) is the crude form of Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances Autophagy, inhibits oxidative stress and Apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P1070A

Amylin, amide, human TFA DAP amide, human TFA	Amylin Receptor	Metabolic Disease
Amylin, amide, human TFA, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human TFA inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .

HY-P10735

GIP (mouse) gastric inhibitory polypeptide(mouse); GIP(1-42) (mouse)	Lipase Apoptosis	Metabolic Disease
GIP (Gastric inhibitory polypeptide) (mouse) is a gastrointestinal hormone that is secreted by the intestinal K cells, and also expressed in and secreted from pancreatic islets. GIP (mouse) promotes insulin secretion from pancreatic β cells via the G-protein-coupled GIP receptor (GIPR). GIP (mouse) promotes pancreatic β cell proliferation and inhibits apoptosis. GIP (mouse) also exerts direct lipogenic effects on adipose tissue .

HY-P1070

Amylin, amide, human DAP amide, human	Amylin Receptor	Metabolic Disease
Amylin, amide, human, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .

HY-114118S1

Semaglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P3579

Gastric Inhibitory Peptide, porcine GIP (1-42), porcine	Insulin Receptor	Metabolic Disease
Gastric Inhibitory Peptide (GIP (1-42)), porcine is a porcine glucose-dependent insulinotropic polypeptide and inhibitor of pentagastrin-stimulated gastric acid secretion. Gastric Inhibitory Peptide, porcine stimulates endogenous somatostatin release. Gastric Inhibitory Peptide, porcine acts in a dose- and time-dependent manner in conscious, chronic gastric fistula-equipped rats .

HY-125556

Tetragastrin 1 Publications Verification Cholecystokinin tetrapeptide; CCK-4	Cholecystokinin Receptor	Metabolic Disease
Tetragastrin (Cholecystokinin tetrapeptide; CCK-4) is the C-terminal tetrapeptide of gastrin. Tetragastrin can stimulate gastric secretion . Tetragastrin is a Cholecystokinin (CCK-4) receptor agonist . Gastric mucosal protection .

HY-P0253

Xenopsin	Neurotensin Receptor	Metabolic Disease
Xenopsin, a neurotensin-like octapeptide from Xenopus laevis skin . Xenopsin is an inhibitor of Tetragastrin stimulated gastric acid secretion .

HY-P1139

Cortistatin-8 PCFWKTCK	GHSR	Metabolic Disease
Cortistatin-8 (CST-8; PCFWKTCK), a neuropeptide, is a GHS-R1a antagonist by counteracting the response of ghrelin on gastric acid secretion. Cortistatin-8 can modulate GH release from somatotroph cells. Cortistatin-8 is a synthetic CST-analogue devoid of any binding affinity to SST-R but capable to bind the GHS-R1a. Cortistatin-8 can exert antagonistic effects on ghrelin actions either in vitro or in vivo in animals .

HY-P2416

Gastrin I, rat Rat Gastrin-17	Cholecystokinin Receptor	Endocrinology
Gastrin I, rat (Rat Gastrin-17) is a peptide hormone, can stimulate gastric acid secretion potently .

HY-P1784A

Secretin, canine TFA	Secretin Receptor	Endocrinology
ecretin, canine TFA is an endocrine hormone that stimulates the secretion of bicarbonate-rich pancreatic fluids. Secretin, canine TFA can regulates gastric chief cell function and paracellular permeability in canine gastric monolayers by a Src kinase-dependent pathway .

HY-103281

Litorin	Bombesin Receptor	Metabolic Disease
Litorin, an amphibian bombesin peptide derivative, is an bombesin receptor agonist. Litorin stimulates the contraction of smooth muscle, stimulates gastrin, gastric acid, and pancreatic secretion, and suppresses the nutriment in vivo .

HY-P1806A

Gastrin I (1-14), human TFA	Cholecystokinin Receptor	Metabolic Disease Endocrinology
Gastrin I (1-14), human TFA is 1-14 fragment of human gastrin I peptide. Gastrin I is an endogenous, gastrointestinal peptide hormone. Gastrin is the major hormonal regulator of gastric acid secretion .

HY-P2541A

GIP (1-30) amide, porcine TFA 1 Publications Verification	Insulin Receptor	Metabolic Disease
GIP (1-30) amide, porcine TFA is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

HY-P5390A

GIP, rat TFA	Peptides	Others
GIP, rat TFA is a bioactive peptide of rat origin. (GIP (glucose-dependent insulinotropic polypeptide or also known as gastric inhibitory polypeptide) is a 42-amino acid peptide released by K cells in the duodenum and jejunum in response to food intake. GIP and GLP (gastric-like peptide) are both intestinal A member of the insulinotropic hormone peptide family that stimulates insulin secretion from pancreatic beta cells and appears to also promote beta cell proliferation and beta cell survival. Recent studies suggest that GIP plays a role in lipid homeostasis and may play a role in the pathogenesis of obesity function in the mechanism.

HY-P11320

Davalintide	Amylin Receptor CGRP Receptor	Metabolic Disease
Davalintide is an Amylin (HY-P1464)-mimetic peptide with greater potency and longer-lasting effects. Davalintide is a potent agonist of amylin receptor (IC₅₀ = 0.04 nM), calcitonin receptor (IC₅₀ = 0.06 nM) and calcitonin related peptide receptor (CGRP receptor) (IC₅₀ = 3.1 nM). Davalintide shows stronger potency to Amylin to activate cyclic AMP production through the calcitonin receptor (EC₅₀ = 1.4 nM). Davalintide regulates blood sugar and weight through various mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide can be used for the studies of anti-obesity and anti-diabetes .

HY-P1806

Gastrin I (1-14), human	Cholecystokinin Receptor	Metabolic Disease Endocrinology
Gastrin I (1-14), human is 1-14 fragment of human gastrin I peptide. Gastrin I is an endogenous, gastrointestinal peptide hormone. Gastrin is the major hormonal regulator of gastric acid secretion .

HY-P2541

GIP (1-30) amide, porcine	Insulin Receptor	Metabolic Disease
GIP (1-30) amide, porcine is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

HY-103545

GIP (1-39) gastric inhibitory peptide (1-39) (porcine)	Insulin Receptor	Metabolic Disease
GIP (1-39) (Gastric inhibitory peptide (1-39) (porcine)) is an insulinotropic peptide that stimulats insulin secretion from rat pancreatic islets. GIP (1-39) at 100 nM was able to significantly increase intracellular Ca ²⁺ concentration ([Ca ²⁺]_i), and capable of enhancing exocytosis .

HY-P5390

GIP, rat	Peptides	Others
GIP, rat is a biological active peptide. (GIP (Glucose-dependent Insulinotropic Polypeptide or also known as Gastric Inhibitory Polypeptide) is a 42-amino acid peptide released by the K cells of the duodenum and jejunum in response to food intake. GIP, together with GLP (Gastric-like Peptide) are members of the hormone peptide family of Incretins which stimulate insulin secretion from pancreatic islet β-cells, and also appears to promote beta cell proliferation and beta cell survival. Recent studies suggest that GIP plays a role in lipid homeostasis and possibly in the pathogenesis of obesity.)

HY-P3577

[Tyr0] Gastric Inhibitory Peptide (23-42), human	Insulin Receptor	Metabolic Disease
[Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research .

HY-P1784

Secretin, canine	Secretin Receptor	Endocrinology
Secretin, canine is an endocrine hormone that stimulates the secretion of bicarbonate-rich pancreatic fluids. Secretin, canine can regulates gastric chief cell function and paracellular permeability in canine gastric monolayers by a Src kinase-dependent pathway .

HY-P0253A

Xenopsin TFA	Neurotensin Receptor	Metabolic Disease
Xenopsin TFA, a neurotensin-like octapeptide from Xenopus laevis skin . Xenopsin TFA is an inhibitor of Tetragastrin stimulated gastric acid secretion .

HY-103276

Alytesin	Endogenous Metabolite	Cardiovascular Disease Neurological Disease
Alytesin, a bombesin-like peptide, is found in extracts of the skin of Alytes obstetricans. Alytesin reduces gastric acid secretion and induces hypertension. Alytesin also induces short-term anorexigenic effects in neonatal chicks

HY-114118C

Semaglutide sodium	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide sodium is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide sodium promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide sodium also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide sodium has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide sodium can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Art. -Nr.	Produktname	Target	Research Area	Image

HY-P991257

MK-1966 1 Publications Verification	Interleukin Related CXCR MHC	Cancer
MK-1966 is an anti-IL-10 antibody. MK-1966 inhibits secretion of cytokines from activated macrophages, production of CC and CXC chemokines, and a TH1 response, down-regulates MHC and costimulatory molecules on dendritic cells (DCs), and induces regulatory T cells. MK-1966 can be used for the research of cancer , such as gastric cancer .

HY-P990690

Volrustomig MEDI-5752	PD-1/PD-L1 CTLA-4	Cancer
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1 ⁺ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1 ⁺ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer .

Art. -Nr.	Produktname	Category	Target	Chemical Structure

HY-N3031

Grosvenorine	Infection Flavonols Structural Classification Flavonoids Classification of Application Fields Cucurbitaceae Phenols Polyphenols Siraitia grosvenorii (Swingle) C. Jeffrey ex Lu et Z. Y. Zhang Plants Disease Research Fields Source Classification	Bacterial Apoptosis Bcl-2 Family MDM-2/p53 Glutathione Peroxidase SOD TNF Receptor Interleukin Related
Grosvenorine is an orally active flavonoid glycoside found in S. grosvenorii. Grosvenorine exhibits antibacterial, antioxidant and antiinflammation activities. Grosvenorine can induce apoptosis and increases anti-apoptotic Bcl-2 protein expression and reduces pro-apoptotic P53 protein expression in gastric tissues. Grosvenorine enhances mucin/glycoprotein secretion, regulates gastric pH, and reduces gastric lesion incidence.Grosvenorine increases glutathione peroxidase, catalase, and SOD levels, reduces lipid peroxidation (MDA), and lowers TNF-α and IL-6 levels. Grosvenorine can be used for the researches of bacterial infection and Gastric ulcer .

HY-N1510

Kaempferol 3-O-gentiobioside	Flavonols Structural Classification Flavonoids Sauropus spatulifolius Beille Classification of Application Fields Phenols Polyphenols Metabolic Disease Euphorbiaceae Plants Disease Research Fields Source Classification	Glycosidase Notch Toll-like Receptor (TLR) NF-κB Mucin Reactive Oxygen Species (ROS) Bacterial TGF-beta/Smad Anaplastic lymphoma kinase (ALK)
Kaempferol 3-O-gentiobioside is an orally active flavonoid, with a K_a value of 57 µM against human NOTCH1 and an IC₅₀ value of 50 μM against α-glucosidase. Kaempferol 3-O-gentiobioside inhibits the NOTCH signaling pathway. It downregulates the expression of TLR4 and NLRP3, and suppresses the activation and nuclear translocation of NF-κB. Kaempferol 3-O-gentiobioside inhibits the expression of MUC5AC, reduces nitrite and ROS levels, and attenuates excessive mucus secretion. It exhibits antibacterial activity, reducing the formation and growth of MRSA biofilms. Kaempferol 3-O-gentiobioside blocks the TGF-β/ALK5/Smad signaling pathway and inhibits epithelial-mesenchymal transition. It suppresses the proliferation, migration, invasion and metastatic growth of tumor cells. Kaempferol 3-O-gentiobioside alleviates airway inflammation and mucus hypersecretion in mice with allergic asthma . It reduces the volume of ovarian cancer xenografts in mice. Kaempferol 3-O-gentiobioside can be used in research related to allergic asthma, diabetes, MRSA infection, breast cancer, gastric cancer and ovarian cancer .

HY-P0253

Xenopsin	Natürliche Produkte Animals Classification of Application Fields Metabolic Disease Disease Research Fields Source Classification	Neurotensin Receptor
Xenopsin, a neurotensin-like octapeptide from Xenopus laevis skin . Xenopsin is an inhibitor of Tetragastrin stimulated gastric acid secretion .

HY-103281

Litorin	Alkaloids Animals Classification of Application Fields Metabolic Disease Solanaceae Plants Disease Research Fields Datura metel Linn. Indole Alkaloids Source Classification	Bombesin Receptor
Litorin, an amphibian bombesin peptide derivative, is an bombesin receptor agonist. Litorin stimulates the contraction of smooth muscle, stimulates gastrin, gastric acid, and pancreatic secretion, and suppresses the nutriment in vivo .

HY-118367

A 80915A	Microorganisms Antibiotics Source Classification	Na+/K+ ATPase Proton Pump
A 80915A is a seminaphthoquinone produced by Streptomyces and is a potent inhibitor of Na+/K+ ATPase involved in gastric acid secretion.

HY-N3031R

Grosvenorine (Standard)	Flavonols Structural Classification Flavonoids Cucurbitaceae Phenols Polyphenols Siraitia grosvenorii (Swingle) C. Jeffrey ex Lu et Z. Y. Zhang Plants Source Classification	Reference Standards Bacterial Apoptosis Bcl-2 Family MDM-2/p53 Glutathione Peroxidase SOD TNF Receptor Interleukin Related
Grosvenorine (Standard) is the analytical standard of Grosvenorine. This product is intended for research and analytical applications. Grosvenorine is an orally active flavonoid glycoside found in S. grosvenorii. Grosvenorine exhibits antibacterial, antioxidant and antiinflammation activities. Grosvenorine can induce apoptosis and increases anti-apoptotic Bcl-2 protein expression and reduces pro-apoptotic P53 protein expression in gastric tissues. Grosvenorine enhances mucin/glycoprotein secretion, regulates gastric pH, and reduces gastric lesion incidence.Grosvenorine increases glutathione peroxidase, catalase, and SOD levels, reduces lipid peroxidation (MDA), and lowers TNF-α and IL-6 levels. Grosvenorine can be used for the researches of bacterial infection and Gastric ulcer .

HY-N15354

Jujubasaponin IV	Triterpenes Structural Classification Tetracyclic Triterpenoids Terpenoids Plants Actaea simplex (DC.) Wormsk. ex Fisch. & C. A. Mey. Rhamnaceae Source Classification	Others
Jujubasaponin IV is a triterpenoid saponin compound found in Zizyphi Fructus. Animal studies have shown that Jujubasaponin IV possesses certain anti-ulcer activity, possibly through mechanisms such as enhancing the gastric mucosal barrier or inhibiting gastric acid secretion. Jujubasaponin IV can be used in research on digestive system diseases, particularly in the study of gastric ulcer mechanisms .

Art. -Nr.	Produktname	Chemical Structure

HY-114118S3

Semaglutide-13C6,15N TFA

Semaglutide- ¹³C₆, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S1

Semaglutide-d8 tetraTFA

Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8

Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-B0113S

Omeprazole-d3

1 Publications Verification

Omeprazole-d₃ (H 16868-d₃) is deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .

HY-B0113S3

Omeprazole-13C,d3

Omeprazole- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .

HY-17021S1

Esomeprazole-d3
Esomeprazole-d₃ is deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-17623S

Tegoprazan-d6

Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC₅₀ values ranging from 0.29-0.52 μM for porcine, canine, and human H ⁺/K ⁺-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .

HY-B0377S

Famotidine-13C,d3
Famotidine- ¹³C,d₃ is the ¹³C- and deuterium labeled Famotidine. Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

HY-W707517

Famotidine-d4
Famotidine-d₄ (MK-208-d₄) is deuterium labeled Famotidine. Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion .

HY-17023S

Esomeprazole-d6 sodium
Esomeprazole-d₆ sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-B0310S

Nizatidine-d3
Nizatidine-d₃ is the deuterium labeled Nizatidine. Nizatidine is a potent and orally active histamine H2 receptor antagonist, can be used for the research of stomach?and?intestines ulcers. Nizatidine works by decreasing the secretion of gastric?acid the stomach makes and prevent ulcers from coming back after they have healed in animal models .

HY-W719463

Rabeprazole sulfide-d4

Rabeprazole sulfide-d₄ is the deuterium labeled Rabeprazole Sulfide (HY-W003467). Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H+/K+)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of H. pylori. Rabeprazole has the potential for various peptic diseases treatment .

HY-B0377S1

Famotidine-13C
Famotidine- ¹³C (MK-208- ¹³C) is ¹³C labeled Famotidine. Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

HY-17021S

Esomeprazole-d3 sodium
Esomeprazole-d₃ (sodium) is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-W777002

Famotidine-13C3
Famotidine- ¹³C₃ (MK-208- ¹³C₃) is the ¹³C-labeled Famotidine (HY-B0377). Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

HY-17021S2

Esomeprazole-d3 potassium
Esomeprazole-d₃ potassium is deuterated labeled Esomeprazole (HY-17021). Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-17037S1

Pirenzepine-d8 dihydrochloride

Pirenzepine-d₈ (LS 519-d₈; Pirenzepin-d₈) dihydrochloride is a deuterium labeled Pirenzepine (dihydrochloride) (HY-17037). Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells .

HY-17037AS

Pirenzepine-d11

Pirenzepine-d₁₁ (LS 519 (free base)-d₁₁; Pirenzepin-d₁₁; Gastrozepin-d₁₁) is the deuterium labeled Pirenzepine (HY-17037A). Pirenzepine (LS 519 free base) is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine shows anti-proliferative activity to cancer cells .

HY-B0113S4

Omeprazole-d3 sodium

Omeprazole-d₃ sodium is deuterated labeled Omeprazole (HY-B0113). Omeprazole sodium (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole sodium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sodium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sodium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sodium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sodium aslo has neuroprotective and antibacterial effects .

HY-B0281AS

Ranitidine-d6 hydrochloride

Ranitidine-d₆ hydrochloride is the deuterium labeled Ranitidine hydrochloride (HY-B0281A) . Ranitidine hydrochloride is a potent, selective and orally active histamine H2-receptor antagonist that inhibits gastric secretion. Ranitidine hydrochloride antagonizes Histamine (HY-B1204)-induced increases of the guinea-pig isolated rat atrium and Histamine-induced relaxations of the rat isolated uterine horn, with pA₂ values of 7.2 and 6.95, respectively. Ranitidine hydrochloride inhibits breast tumor development and spread in mice .

HY-B0693S

Ranitidine-d6

Ranitidine-d₆ is the deuterium labeled Ranitidine (HY-B0693). Ranitidine is a potent, selective and orally active histamine H2-receptor antagonist that inhibits gastric secretion. Ranitidine antagonizes Histamine (HY-B1204)-induced increases of the guinea-pig isolated rat atrium and Histamine-induced relaxations of the rat isolated uterine horn, with pA2 values of 7.2 and 6.95, respectively. Ranitidine inhibits breast tumor development and spread in mice .

HY-B0113S2

Omeprazole sulfone (methoxy-d3)

Omeprazole sulfone (methoxy-d₃) is the deuterium labeled Omeprazole sulfone. Omeprazole sulfone (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole sulfone competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sulfone inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sulfone inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sulfone alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sulfone aslo has neuroprotective and antibacterial effects .

HY-B0113S5

Omeprazole-d6

Omeprazole-d₆ (H 16868-d₆) is deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .

HY-B0113S1

Omeprazole-d3-1

Omeprazole-d₃-1 is the deuterium labeled Omeprazole. Omeprazole-1 (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole-1 competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole-1 inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole-1 inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole-1 alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole-1 aslo has neuroprotective and antibacterial effects .

Online-Anfrage

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Anrede			Country or Region *
Name des Antragstellers *			Name der Organisation *
Department *
E-Mail-Addresse *			Produktname *
Art. -Nr.			Requested quantity *
Telefonnummer *
Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

gastric acid secretion and

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products